Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Re-evaluating hereditary breast and ovarian cancer risk: clinical impact of updated multigene panel sequencing and genetic counseling.

Familial cancer - 27 Mar 2026

Gislinge Julie Isabelle Plougmann, Byrjalsen Anna, Naver Klara Vinsand, Clausen Helle Vibeke, Ravn Pernille, Petersen Kresten Rubeck, Wadt Karin A W

Abstract excerpt

An increased lifetime risk of ovarian cancer is observed among women with a family history of ovarian cancer, with or without breast cancer, as well as among carriers of pathogenic germline variants in ovarian cancer (OC) predisposition genes. Over the past two decades, additional OC–associated genes beyond BRCA1/2 have been identified, highlighting the need for updated genetic evaluation in women previously...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Denmark

Share to Genetic Counseling

Share to Germ-Line Mutation

Share to Hereditary Breast and Ovarian Cancer Syndrome

Share to Ovarian Neoplasms

Share to Risk Assessment

Source

Open in PubMed Open full text

Identifiers

PMID: 41894033
DOI: 10.1007/s10689-026-00547-2
PMCID: PMC13031182

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Re-evaluating hereditary breast and ovarian cancer risk: clinical impact of updated multigene panel sequencing and genetic counseling.PMID 41894033Read ↗

Breast and Ovarian Cancer Among Individuals Undergoing BRCA1 and BRCA2 Testing.Semantic proximity Read ↗

Utility of Expedited Hereditary Cancer Testing in the Surgical Management of Patients with a New Breast Cancer Diagnosis.Semantic proximity Read ↗

Hereditary Breast and Ovarian Cancer: An Updated Primer for OB/GYNs.Semantic proximity Read ↗

High detection rate from genetic testing in BRCA-negative women with familial epithelial ovarian cancer.Semantic proximity Read ↗

Germline BRCA testing is moving from cancer risk assessment to a predictive biomarker for targeting cancer therapeutics.Semantic proximity Read ↗

Results of breast cancer risk assessment and hereditary cancer genetic testing in community obstetrics and gynaecology practice following a prospective quality Improvement initiative.Semantic proximity Read ↗

SEOM clinical guidelines in hereditary breast and ovarian cancer (2019).Semantic proximity Read ↗

Real-world genetic testing data of ovarian cancer patients: Informing counseling and risk reduction in patients over age seventy.Semantic proximity Read ↗

An analysis of the impact of annual cancer genetic testing guideline updates on a past patient population.Semantic proximity Read ↗

Impact of non-BRCA genes in the indication of risk-reducing surgery in hereditary breast and ovarian cancer syndrome (HBOC).Semantic proximity Read ↗

NSGC Practice Guideline: Risk Assessment and Genetic Counseling for Hereditary Breast and Ovarian CancerSemantic proximity Read ↗

Clinical Utility of Universal Germline Genetic Testing for Patients With Breast Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.